XTalks
APRIL 10, 2023
The adoption of decentralized clinical trial (DCT) approaches has increased exponentially. Tools such as electronic consent, telehealth appointments and wearable devices have enabled investigators to contact trial participants virtually. What are some barriers to adopting DCT methods in oncology trials?
pharmaphorum
SEPTEMBER 16, 2020
Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial. The post Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy appeared first on.
pharmaphorum
JANUARY 27, 2021
Regeneron is considering an emergency filing for its antibody cocktail REGEN-COV to protect people against COVID-19 after early trial results showed it conferred 100% protection against symptomatic infection. There were fewer total high viral shedding weeks – 22 weeks in the placebo group compared with none in the REGEN-COV group.
Expert insights. Personalized for you.
97 
Let's personalize your content